NORML

OCTOBER 21, 2019

The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials. Since 1968, the agency has only licensed the University of Mississippi to engage in the growing of cannabis for FDA-approved clinical research.

DEA

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials

Veriheal

MARCH 20, 2023

Psilocybin Policies Around the Nation Let’s explore where psilocybin is legal, decriminalized, and on the ballot across U.S. While decriminalization decreases the negative impact of legal issues, it does not provide accessible, safe, and regulated psilocybin for those seeking treatment. Texas This year, Texas Gov.

Clinical Trials

Cannabis Law Report

JUNE 20, 2021

Patient access. I’ve been working hard with some great advocates for patient access in the UK and this position will give me the opportunity to ensure that patients will have access to the high-quality medicines and products they deserve.”.

Supply Chain

SpeedWeed

JULY 6, 2021

Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”.

Policy

Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Access to Psychedelic Therapies and Equity in Emerging Psychedelics Industries. Background.

Law

Project CBD

FEBRUARY 28, 2023

13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e., Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022.

CBD

Cannabis Law Report

MARCH 7, 2022

The UK is one of the biggest producers of medicinal cannabis, but few patients have access to these medicines. High-profile cases of parents campaigning for access to cannabis oil for severe and rare forms of epilepsy in their children are the most recent in a long line of controversies over cannabis and cannabis-based medicines.

Clinical Trials

Cannabis Law Report

JUNE 14, 2022

There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. PAREA is coming together to address those challenges and provide evidence-based policy recommendations and expertise to the EU policymakers.

Access

Project CBD

NOVEMBER 11, 2023

We rate levels of evidence, and a high level may be a controlled randomized clinical trial (RCT), but there are also observational studies. states there are dispensaries where most people have access to cannabis drugs. But they’re there and people can have access to them. Dr. Weil: In most U.S.

Medicine

Veriheal

MAY 12, 2021

In light of such, and the fact that cancer is a common qualifying condition for cannabis, this research team took to expanding the available basic information on cannabis in the cancer population in order to provide clinical trial designers with better information needed for planned studies.

Patients

Cannabis Law Report

JUNE 24, 2022

Scutari’s proposed “Psilocybin Behavioral Health Access and Services Act” represents a bold development in the psychedelics reform movement that’s rapidly spread in state legislatures and through citizen-led initiatives throughout the country in recent years. Full story at.

Clinical Trials

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). That access would be available under the auspices of having a chronic, untreatable mood disorder.

Legalization

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy

Cannabis Law Report

JANUARY 14, 2020

CLICK IMAGE TO ACCESS COMMITTEE INFO PAGE. Senior Policy Advisor, Diversion Control Division. Amidst growing evidence that marijuana can be used to effectively treat post-traumatic stress disorder , this bill from California Democrat Barbara Lee focuses on greatly expanding access to medical marijuana for veterans. Legislation.

Clinical Trials

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting.

Research and Development

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. However, ever-evolving cannabis regulations in other Asian countries like Thailand have inspired lawmakers to adopt policy change in Japan.

Legalization

Cannabis Law Report

FEBRUARY 10, 2022

The report includes: A deep dive into psychedelic drug policy reform efforts and successes in 2021, with a focus on key jurisdictions including the U.S. A look at key research and clinical trials that were published in 2021, with analysis of themes like microdosing and SSRI interactions. Access the PDF here. and Canada.

Clinical Trials

Cannabis Law Report

OCTOBER 10, 2021

Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis. Provide guidance on clinical trials and plays integral role in bringing new product innovations to different markets in Europe (and beyond). pharmacology, toxicology, chemistry).

Clinical Trials

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy

MMJ Recs

MAY 9, 2024

As such, we provide you with a comprehensive guide for veterans using medical cannabis and the various aspects of it, including its usage, accessibility, legal considerations, healthcare options, and available resources. Navigating the complexities surrounding the Veterans Administration and medical cannabis can be daunting.

Research and Development

Cannabis Law Report

NOVEMBER 29, 2019

Different legislation across EU countries on prescribing cannabis-based medicines can hinder patients’ access to their treatment when they travel abroad, EUMCA said. Lack of clinical trials is a major reason why doctors are cautious about the drug.

Medicine

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Key Responsibilities. Position Requirements.

Research and Development

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map. Where Laws Are Changing.

Law

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. If compelling evidence emerges regarding the benefits of MMJ for additional conditions, this may influence future policy changes.

Law

Cannabis Law Report

NOVEMBER 23, 2021

In a draft paper, Patents on Psychedelics: The Next Legal Battlefront of Drug Development , Senior Fellow at Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics Mason Marks and Harvard Law School Professor I.

Law

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials

MMJ Recs

JULY 5, 2024

Numerous clinical trials are underway to further investigate THC’s efficacy, safety, and potential interactions with other medications as well. These trials aim to provide more conclusive evidence for its use in mainstream medicine. Legal Status of THC THC’s legal status varies in the US.

THC

MMJ Recs

DECEMBER 22, 2023

This shift can be attributed to increased access to information, a more liberal societal outlook, and a willingness to explore alternative healthcare options. The STATES Act, for example, represents a step toward allowing states to determine their cannabis policies without federal interference.

Marijuana

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. “; 4) Article 11 shall be worded as follows: ” Article 11. .”;

Seed-To-Sale

Cannabis Law Report

JULY 15, 2019

Law 33/2018 set the framework for the regulation of the use of cannabis-based medicinal products, preparations and substances that would effectively allow Portuguese patients to access medical cannabis What really has changed during the last year?

Medicine

SpeedWeed

JULY 23, 2021

For some, that struggle has inspired them to spread affordable, accessible resources for better mental health. Ideally, nootropic supplements contain a variety of natural products that have been shown to improve cognitive function in clinical trials. You can unsubscribe from Leafly email messages anytime. View original article.

CBD

MMJ Recs

AUGUST 1, 2024

As the legal landscape evolves, increasing numbers of patients can access medical marijuana, leading to more research and better regulation. Legal Considerations for HIV/AIDS Patients Using Medical Marijuana The legal landscape of medical marijuana varies widely by region, influencing access and use for HIV/AIDS patients.

Patients

Cannabis Law Report

MAY 1, 2022

The Psychedelic Bar Association (PBA) is an association of attorneys and legal professionals dedicated to solving the novel legal and policy issues impacting the emerging psychedelics sector. The PBA Religious Use Committee provides expertise around the intersections of law, policy, psychedelics, and religion.

Safety

The Joint Blog

OCTOBER 21, 2020

Due to the updated hemp act being relatively new, lawmakers are still studying and formulating policies that can better improve the industry while regulating it for the safety of users. Although scientific research on this has a long way to go, previous studies and clinical trials have produced promising results.

CBD